Aegerion Pharmaceuticals, Inc. (AEGR) Message Board
-
Lomitapide will outsell Kynamro 10-1 or higher
The marketshare between Lomitapide and Kynamro will be heavily slanted towards Lomitapide given effectiveness, safety, and probability for success. I fully expect Lomitapide to outsell Kynamro overwhelmingly, especially once patients start taking both drugs and compare actual results.
-
I think exactly the opposite. Unless you have these juxta patients have their diet watched as closely as they had it watched in their study there is going to be a huge drop off in use. Xenical had over $850 million in sales in the second year. Last year sales of Xenical worldwide was only $50 million and that included sales from the OTC form of the drug.....which is a lower dies but still very bothersome forbthat diarrhea side effect. I think junta will have diarrhea side-effects like five fold that of Xenical. Also, the FDA is going to let a single armed 29 patient study suffice in the pediatric population. Unbelieveable that the fiimsy study for the adults made it through. Mr. Beer won't be able to fast talk that one, and expect a $70 million dollar bill to get even the most modest study through for that indication. t
- 4 Replies to jetmanbash
-
But Jet....think of all the diapers aegr can sell...let's see...4/per day x 365 days x $800/day (like their pills
-
Are you joking or confused? Xenical the diet drug? You are comparing people who are losing the ability to move from homozygous familial hypercholesterolemia with people who want to lose weight so they look good in a swimsuit? You are lost. Go to the Vivus board.
-
It really makes no difference. If AEGR is not bought out, the stock will never go over 30.
-
Using my iPad with bad typing, the main thing to note is that juxta will have more diarrhea than even Xenical has. And the CEO stating they are going after a peds indication will be much more costly, not as easy as they had when they walzted into that preliminary committee meeting with a 23 patient single-armed study. t
-